Jpmorgan Chase & CO Alkermes Plc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALKS
# of Institutions
395Shares Held
176MCall Options Held
558KPut Options Held
427K-
Black Rock Inc. New York, NY29.1MShares$811 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$516 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10MShares$280 Million0.03% of portfolio
-
State Street Corp Boston, MA8.21MShares$229 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.41MShares$179 Million1.86% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.58B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...